• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

Abbott launches study of next-gen ablation catheter

August 4, 2020 By Danielle Kirsh

TactiFlex sensor-enabled ablation catheter Abbott
The TactiFlex sensor-enabled ablation catheter [Image courtesy of Abbott]
Abbott (NYSE:ABT) today announced it has enrolled the first participants in its TactiFlex PAF IDE study to evaluate the performance of the TactiFlex sensor-enabled ablation catheter.

Abbott designed the catheter to treat people suffering from paroxysmal atrial fibrillation (PAF) with symptoms that are unable to be managed by medication.

TactiFlex combines Abbott’s contact force-sensing technology within the TactiCath SE catheter with a catheter tip design found in the company’s Flexibility irrigated ablation catheter. The combination of the two technologies allows for an appropriate amount of pressure to the heart walls with proper fluid rates to cool the tissues, according to Abbott.

Abbott’s TactiFlex PAF IDE study will enroll 355 patients at multiple sites globally. Participants will receive an ablation procedure using the TactiFlex Ablation Catheter SE. Abbott will submit data collected from the study for global regulatory approvals.

“The TactiFlex device builds on prior generations of successful technology, giving me confidence that Abbott will continue providing options to effectively treat people living with recurrent episodes of atrial fibrillation,” said Prash Sanders, director for the Center for Heart Rhythm Disorders at The Royal Adelaide Hospital in Adelaide, Australia.

Atrial fibrillation is the most common type of treated heart arrhythmia, according to the Centers for Disease Control and Prevention. It is estimated that between 2.7 million and 6.1 million people have AFib in the U.S.

“Abbott is focused on bringing innovation to physicians that can improve how people with atrial fibrillation are treated. The TactiFlex Ablation Catheter, SE brings the best of Abbott’s ablation technologies into a single catheter,” said Mike Peterson, senior VP of Abbott’s electrophysiology and heart failure businesses.

The TactiFlex sensor-enabled ablation catheter is currently under clinical evaluation and is not yet available commercially.

Filed Under: Catheters Tagged With: Abbott

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS